Navigation Links
Genmab's Financial Calendar for 2008
Date:1/31/2008

COPENHAGEN, Denmark, January 31 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) announces its financial calendar for 2008 as follows:

EVENT DATE

Publication of the Annual Report for 2007 Monday, March 31, 2008

Annual General Meeting 2008 Wednesday, April 23, 2008

Publication of the Interim Report for the Wednesday, May 28, 2008

first quarter 2008

Publication of the Interim Report for the Wednesday, August 27, 2008

first half 2008

Publication of the Interim Report for the Wednesday, October 29, 2008

first nine months 2008

Publication of the financial reports will be after market close on the date of the event.

About Genmab A/S

Genmab is a leading international biotechnology company focused on developing fully human antibody therapeutics for unmet medical needs. Using unique, cutting-edge antibody technology, Genmab's world class discovery and development teams have created and developed an extensive pipeline of products for potential treatment of a variety of diseases including cancer and autoimmune disorders. As Genmab advances towards a commercial future, we remain committed to our primary goal of improving the lives of patients who are in urgent need of new treatment options. For more information on Genmab's products and technology, visit http://www.genmab.com.

This press release contains forward looking statements. The words "believe", "expect", "anticipate", "intend" and "plan" and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with product discovery and development, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. Genmab is not under an obligation to up-date statements regarding the future following the publication of this release; nor to confirm such statements in relation to actual results, unless this is required by law.

Genmab(R); the Y-shaped Genmab logo(R); HuMax(R); HuMax-CD4(R); HuMax-CD20(R); HuMax-EGFr(TM); HuMax-IL8(TM); HuMax-TAC(TM); HuMax-HepC(TM); HuMax-CD38(TM); HuMax-CD32b(TM) and UniBody(R) are all trademarks of Genmab A/S.

Contact:

Helle Husted,

Sr. Director,

Investor Relations,

T: +45-33-44-77-30,

M: +45-25-27-47-13,

E: hth@genmab.com.


'/>"/>
SOURCE Genmab A/S
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Monogram Biosciences Announces Fourth Quarter 2007 Financial Results Conference Call
2. CV Therapeutics to Announce 2007 Fourth Quarter and Year End Financial Results on Tuesday, February 26, 2008
3. Carrington Retains Milkie/Ferguson to Explore Financial Alternatives
4. Cynosure to Announce Fourth-Quarter and Full Year 2007 Financial Results on February 12
5. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
6. ARIUS announces fourth quarter and year-end fiscal 2007 financial results
7. 3SBio Inc. Announces Appointment of Kevin Sow Peng Teo as Chief Financial Officer
8. Cardica Announces Fiscal 2008 Second Quarter Financial Results and Business Progress
9. Neurocrine Biosciences Announces Conference Call and Webcast to Present Fourth Quarter and Year End 2007 Financial Results
10. PAREXEL Reports Second Quarter Fiscal Year 2008 Financial Results
11. Lorus Therapeutics Appoints Peter Korth as Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... April 29, 2016 , ... Amendia, Inc., a leading ... today announced the completion of a significant transaction and partnership that positions Amendia ... and partners. Kohlberg & Company, L.L.C. (“Kohlberg”), a leading private equity firm ...
(Date:4/29/2016)... , April 29, 2016 Elekta ... latest update to its industry-leading treatment planning software, is ... Monaco version 5.11 provides significant ... attain calculation speeds up to four times faster than ... With the industry,s gold standard Monte Carlo ...
(Date:4/28/2016)... ... April 28, 2016 , ... As part of an ... experts, and expanding its LATAM network and logistics capabilities. Enhancements have been ... their clinical trial projects. , The expansion will provide unmatched clinical trial logistics ...
(Date:4/27/2016)... ... 27, 2016 , ... Most consumers engage with biometrics technology ... secure access, voice recognition for hands-free communication, and facial recognition to help organize ... technology today. But if they asked Joey Pritikin, Vice President of Marketing ...
Breaking Biology Technology:
(Date:4/15/2016)... -- Research and Markets has announced the ...  report to their offering.  ,      ... gait biometrics market is expected to grow at ... Gait analysis generates multiple variables such ... compute factors that are not or cannot be ...
(Date:3/29/2016)... RATON, Florida , March 29, 2016 ... or the "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are ... DNA in ink used in a variety of writing ... theft. Buyers of originally created collectibles from athletes on ... through forensic analysis of the DNA. ...
(Date:3/18/2016)... LONDON , March 18, 2016 ... Established Suppliers of Biometrics, ICT, Manned & Unmanned Vehicles, Physical ... & security companies in the border security market and ... and Europe has led ... your companies improved success. --> defence & ...
Breaking Biology News(10 mins):